Abstract
Protein tyrosine phosphatases (PTPs) constitute a large family of enzymes that can exert both positive and negative effects on signaling pathways. They play dominant roles in setting the levels of intracellular phosphorylation downstream of many receptors including receptor tyrosine kinases and G protein-coupled receptors. As observed with kinases, deregulation of PTP activity can also contribute to cancer. This review will examine a broad array of PTP family members that positively affect oncogenesis in human cancer tissues. We will describe the PTP family, their biological significance in oncology, and how recent progress is being made to more effectively target specific PTPs. Finally, we will discuss the therapeutic implications of targeting these oncogenic PTPs in cancer.
Keywords: Cancer, Inhibitors, dual-specificity phosphatases (DSPs), Oncogene, Protein tyrosine phosphatases, Phosphorylation, Tumor suppressor, G protein-coupled receptors (GPCRs), Amplification, Gynecological Cancers
Anti-Cancer Agents in Medicinal Chemistry
Title: Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Volume: 12 Issue: 1
Author(s): Serge Hardy, Sofi G. Julien and Michel L. Tremblay
Affiliation:
Keywords: Cancer, Inhibitors, dual-specificity phosphatases (DSPs), Oncogene, Protein tyrosine phosphatases, Phosphorylation, Tumor suppressor, G protein-coupled receptors (GPCRs), Amplification, Gynecological Cancers
Abstract: Protein tyrosine phosphatases (PTPs) constitute a large family of enzymes that can exert both positive and negative effects on signaling pathways. They play dominant roles in setting the levels of intracellular phosphorylation downstream of many receptors including receptor tyrosine kinases and G protein-coupled receptors. As observed with kinases, deregulation of PTP activity can also contribute to cancer. This review will examine a broad array of PTP family members that positively affect oncogenesis in human cancer tissues. We will describe the PTP family, their biological significance in oncology, and how recent progress is being made to more effectively target specific PTPs. Finally, we will discuss the therapeutic implications of targeting these oncogenic PTPs in cancer.
Export Options
About this article
Cite this article as:
Hardy Serge, G. Julien Sofi and L. Tremblay Michel, Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/187152012798764741
DOI https://dx.doi.org/10.2174/187152012798764741 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unlocking the Molecular Mechanisms of DNA Repair and Platinum Drug Resistance in Cancer Chemotherapy
Current Drug Therapy The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology The Role of Heat Shock Proteins in Cisplatin Resistance
Anti-Cancer Agents in Medicinal Chemistry ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets The Pathogenesis, Complications and Therapeutic Strategy for Hepatitis C Virus-associated Insulin Resistance in the Era of Anti-viral Treatment
Reviews on Recent Clinical Trials Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA
Current Pharmaceutical Design Prevention of Cancer in the Upper Gastrointestinal Tract with COX-Inhibition. Still an Option?
Current Pharmaceutical Design Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Current Drug Targets Molecular Targets of Omega-3 Fatty Acids for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition New Insights in Testing and Imaging Techniques for Solid Tumor Response Evaluation
Neuroscience and Biomedical Engineering (Discontinued) Cancer-Associated Carbonic Anhydrases and Their Inhibition
Current Pharmaceutical Design Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds